Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ghady Haidar
With
AstraZeneca
This is a prospective study of 500 immunocompromised participants at UPMC health system. EVUSHELD will be given according to the EUA in the United States as a part of standard of care by the patient's health care provider. Patients who receive intramuscular EVUSHELD as standard of care will be enrolled and followed for 12-months. The target sample size is 500 immunocompromised individuals; serum concentrations of AZD7442 will be obtained in all patients at the 6 (or at enrollment if the time point has passed) and 12 month timepoints.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 12 and at least 40 kg
Eligible for EVUSHELD as per the EUA
You may not be if
Active and confirmed COVID-19
Known or suspected pregnancy, concurrent lactation
Any other significant disease, disorder, or finding, in the opinion of the investigator, that may significantly increase the risk to the participant because of participation in the study, affect the ability of the subject to participate in the study, or impair interpretation of the study data
